异柠檬酸脱氢酶1R132H与同源框C10在脑胶质瘤组织的表达及其临床意义

doi:10.19854/j.cnki.1008-2425.2023.03.0002

摘要/Abstract

摘要： 目的探讨分析异柠檬酸脱氢酶1R132H与同源框C10在脑胶质瘤组织的表达及其临床意义。方法选取2018年10月至2020年10月保定市第七医院收治的手术切除的128例脑胶质瘤患者,取其胶质瘤组织标本128份。采用免疫组织化学法检测胶质瘤组织中和正常脑组织中异柠檬酸脱氢酶1(isocitrate dehydrogenase,IDH1)R132H与同源框C10(Homeobox C10,HOXC10)表达情况。分析IDH1R132H、HOXC10表达与脑胶质瘤临床病理特征及预后的关系。结果 IDH1R132H在低级别脑胶质瘤中阳性率为63.46%,在高级别脑胶质瘤中阳性率为14.47%,高级别脑胶质瘤中阳性率低于低级别脑胶质瘤;HOXC10在低级别脑胶质瘤中阳性率为46.15%,在高级别脑胶质瘤中阳性率为77.63%,高级别脑胶质瘤中阳性率高于低级别脑胶质瘤,IDH1R132H、HOXC10表达与脑胶质瘤病理级别有关(P＜0.05)。Spearman等级相关分析结果显示,脑胶质瘤中IDH1R132H表达与HOXC10表达呈负相关关系(r=-0.457,P＜0.05)。年龄、病理级别、术前卡氏功能评分、术后放化疗、IDH1R132H表达和HOXC10表达与脑胶质瘤患者预后有关(P＜0.05);年龄≤45、病理级别低级别、术前卡氏功能评分高、术后放化疗、IDH1R132H阳性患者预后较好(P＜0.05),HOXC10阳性患者预后较差(P＜0.05)。将有统计学意义的因素纳入多因素Cox回归分析,结果显示,病理级别(HR=5.249,95%CI:2.041～13.500)、术后放化疗(HR=4.899,95%CI:2.482～9.671)、HOXC10阳性(HR=2.593,95%CI:1.592～4.225)是影响脑胶质瘤患者预后的独立危险因素(P＜0.05)。结论脑胶质瘤组织中IDH1R132H呈较低表达,HOXC10呈较高表达,二者在脑胶质瘤中表达呈负相关,其表达与患者预后密切相关,可作为预后评估的重要参考指标。

关键词: 异柠檬酸脱氢酶1R132H, 同源框C10, 脑胶质瘤, 预后

Abstract: Objective To investigate the expression and clinical significance of isocitrate dehydrogenase 1R132H and homeobox C10 in glioma tissue.Methods 128 patients with gliomas who underwent surgical resection in Baoding Seventh Hospital from October 2018 to October 2020 were selected,and 128 glioma tissue specimens were collected.Immunohistochemistry was used to detect the expression of isocitrate dehydrogenase(IDH1) R132H and Homeobox C10(HOXC10) in glioma tissue and normal brain tissue.Relationship between the expression of IDH1R132H and HOXC10 and the clinicopathological characteristics and prognosis of glioma was analyzed.Results The positive rate of IDH1R132H was 63.46% in low-grade gliomas and 14.47% in high-grade gliomas,and the positive rate in high-grade gliomas was lower than that in low-grade gliomas;The positive rate was 46.15% in high-grade gliomas,and 77.63% in high-grade gliomas.The positive rate in high-grade gliomas was higher than that in low-grade gliomas.The pathological grade of glioma was related(P＜0.05).The Results of Spearman rank correlation analysis showed that the expression of IDH1R132H in glioma was negatively correlated with the expression of HOXC10(r=-0.457,P＜0.05).Age,pathological grade,preoperative Karnofsky function score,postoperative chemoradiotherapy,IDH1R132H expression and HOXC10 expression were related to the prognosis of patients with glioma(P＜0.05);age≤45,low-grade pathological grade,preoperative Karnofsky function Patients with high scores,postoperative radiotherapy and chemotherapy,and IDH1R132H-positive patients had better prognosis(P＜0.05),while HOXC10-positive patients had poor prognosis(P＜0.05).Statistical factors were included in multivariate Cox regression analysis.The Results showed that pathological grade(HR=5.249,95%CI:2.041~13.500),postoperative chemoradiotherapy(HR=4.899,95%CI:2.482~9.671),HOXC10 positive(HR=2.593,95%CI:1.592~4.225) was an independent risk factor affecting the prognosis of glioma patients(P＜0.05).Conclusion The expression of IDH1R132H in glioma tissue is lower,and the expression of HOXC10 is higher.The expression of the two is negatively correlated in glioma,and its expression is closely related to the prognosis of patients,which can be used as an important reference index for prognosis evaluation.

Key words: Isocitrate dehydrogenase1R132H, Homeobox C10, Glioma, Prognosis

中图分类号:

R739.41

杜云, 王卫中, 刘梦, 姚萌萌. 异柠檬酸脱氢酶1R132H与同源框C10在脑胶质瘤组织的表达及其临床意义[J]. 立体定向和功能性神经外科杂志, 2023, 36(3): 135-140.

Du Yun, Wang Weizhong, Liu Meng, et al. Expression and clinical significance of isocitrate dehydrogenase 1R132H and homeobox C10 in glioma tissue[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2023, 36(3): 135-140.

参考文献

[1] 李敏龙,姜萍,罗敏.异柠檬酸脱氢酶-1基因突变与脑胶质瘤关系的研究进展[J].解放军医药杂志,2020,32(3):69~72.
[2] Clément A,Doyen M,Fauvelle F,et al.In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines[J].NMR Biomed,2021,34(6):e4490.
[3] Alfaro CM,Pirro V,Keating MF,et al.Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry[J].J Neurosurg,2019,132(1):180~187.
[4] 罗刚,喻坚柏,陈涛,等.异柠檬酸脱氢酶1基因突变对替莫唑胺干预下脑胶质瘤U87细胞凋亡的影响[J].安徽医药,2021,25(8):1492~1496.
[5] Ferreira MSV,Sørensen MD,Pusch S,et al.Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation[J].J Neurooncol,2020,147(1):1~14.
[6] Tabei Y,Kobayashi K,Saito K,et al.Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase(IDH)1 gene mutation status[J].Jpn J Clin Oncol,2021,51(1):45~53.
[7] 王樑,潘亚文,屈延,等.2021年世界卫生组织中枢神经系统肿瘤分类(第五版)成人型弥漫性胶质瘤分类解读[J].中国现代神经疾病杂志,2021,21(9):783~790.
[8] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016(7):485~509.
[9] Vuong HG,Tran TTK,Ngo HTT,et al.Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma:the need to further stratify this tumor entity - a meta-analysis[J].Eur J Neurol,2019,26(3):379~387.
[10] 全凯,周荣福,童建国,等.miRNA-324-5p和转录因子叉头框C1在脑胶质瘤中的表达及其临床意义[J].肿瘤研究与临床,2021,33(4):270~275.
[11] Peng H,Huo J,Li B,et al.Predicting Isocitrate Dehydrogenase(IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features[J].J Magn Reson Imaging,2021,53(5):1399~1407.
[12] Nguyen TB,Melkus G,Taccone M,et al.Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS:A Prospective Study[J].J Magn Reson Imaging,2021,53(2):416~426.
[13] 崔敬,佟建洲.HOXC10在人脑胶质瘤中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2020,25(8):513~516.
[14] Jiang WY,Lei QY,Liu SS,et al.The effect of HOXC10 gene on biological behaviors of glioma cells and mechanism in tumor microenvironment[J].Chinese Journal of Oncology,2022,44(3):228~237.
[15] Guan Y,He Y,Lv S,et al.Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway[J].J Drug Target,2019,27(1):60~66.
[16] 石柳,李木子,高勤.异柠檬酸脱氢酶及信号传导和转录活化因子1在星形细胞肿瘤发生发展中的作用[J].中国临床研究,2021,34(11):1553~1555,1560.
[17] Liu J,Cheng C,Jiao J,et al.MircoRNA-129-5p suppresses the development of glioma by targeting HOXC1r[J].Pathol Res Pract,2020,216(4):152868.
[18] Karpel-Massler G,Nguyen TTT,Shang E,et al.Karpel-Massler G,Nguyen TTT,Shang E[J].CNS Drugs,2019,33(12):1155~1166.
[19] 田金成,武艳玮,马霜,等.异柠檬酸脱氢酶1突变对胶质瘤细胞增殖的影响[J].神经解剖学杂志,2021,37(5):533~538.
[20] Yang R,Zhao Y,Gu Y,et al.Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma[J].Oncogene,2020,39(40):6340~6353.
[21] 姜文艺,雷清扬,刘莎莎,等.同源盒基因C10对脑胶质瘤细胞生物学行为的影响及在肿瘤微环境中的作用机制[J].中华肿瘤杂志,2022,44(3):228~237.
[22] Mellinghoff IK,Ellingson BM,Touat M,et al.Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma[J].J Clin Oncol,2020,38(29):3398~3406.
[23] Sung CH,Tsuang FY,Lin CP,et al.Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation[J].Sci Rep,2021,11(1):16489.
[24] Masood M,Anwar RF,Mehmood K,et al.Analysis of Isocitrate dehydrogenase(IDH) mutation in Gliomas:A call for neurosurgeons and pathologists in Pakistan[J].J Pak Med Assoc,2022,72(1):134~140.